Nuscale Power earnings missed by $0.02, revenue fell short of estimates
Director Todd Watanabe of Arcutis Biotherapeutics (NASDAQ:ARQT), sold 11,547 shares of common stock on August 4, 2025, according to a recent SEC Filing. The shares were sold at a weighted average price of $14.3266, for a total transaction value of $165429. The prices for the shares sold ranged from $13.965 to $14.675. The stock, currently trading at $15.33, has shown impressive returns of 68.5% over the past year. According to InvestingPro analysis, the company appears slightly undervalued based on its Fair Value metrics.
The sale reported on the Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.
Following the transaction, Watanabe directly owns 901,569 shares of Arcutis Biotherapeutics. Watanabe also has indirect ownership of shares through various trusts and an LLC. These include 25,410 shares held by The John Franklin Watanabe Trust, 25,410 shares held by The Anderson Prest Watanabe Irrevocable Trust, 57,358 shares held by Watanabe Ventures, LLC, and 124,956 shares held by The Watanabe 2016 Irrevocable Trust.
In other recent news, Arcutis Biotherapeutics announced that the U.S. Food and Drug Administration (FDA) has approved ZORYVE® topical foam 0.3% for treating plaque psoriasis on the scalp and body for individuals aged 12 and older. This approval is notable as it marks the fifth FDA approval for ZORYVE in under three years, broadening treatment options for millions of Americans dealing with plaque psoriasis. H.C. Wainwright analysts reiterated their Buy rating on Arcutis, maintaining a $19 price target following the FDA’s decision, highlighting the foam’s versatility for treating psoriasis in hair-bearing areas. Additionally, Guggenheim has maintained a Buy rating with a $29 price target, noting an increase in Zoryve prescriptions, with foam prescriptions rising to 8,040 from 7,443. Morgan Stanley (NYSE:MS) has also assumed coverage of Arcutis with an Overweight rating and a $20 price target, focusing on Zoryve’s market share gains. H.C. Wainwright further emphasized the strength of recent study data for Zoryve cream, citing its potential for safe, long-term use in atopic dermatitis. The firm expressed confidence in the upcoming Prescription Drug User Fee Act decision for Zoryve cream 0.05%, scheduled for October 13. These developments underscore the growing acceptance and application of Arcutis’ products in dermatological treatments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.